Tetraphase Pharmaceuticals (NASDAQ:TTPH) had its price target lowered by stock analysts at Piper Jaffray Companies to $6.00 in a note issued to investors on Thursday, The Fly reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ target price would indicate a potential upside of 145.90% from the stock’s current price.

Several other brokerages have also issued reports on TTPH. Zacks Investment Research lowered Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, July 7th. B. Riley lifted their price target on Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, August 28th. HC Wainwright lifted their price target on Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, August 28th. WBB Securities upgraded Tetraphase Pharmaceuticals from a “speculative buy” rating to a “buy” rating and set a $7.00 price target on the stock in a research note on Thursday, September 6th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Friday, August 3rd. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $6.16.

Shares of TTPH opened at $2.44 on Thursday. Tetraphase Pharmaceuticals has a 52-week low of $2.05 and a 52-week high of $7.29. The firm has a market capitalization of $145.89 million, a PE ratio of -0.93 and a beta of 2.57.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.18. Tetraphase Pharmaceuticals had a negative return on equity of 67.34% and a negative net margin of 421.64%. The company had revenue of $11.58 million for the quarter, compared to analyst estimates of $2.23 million. On average, sell-side analysts expect that Tetraphase Pharmaceuticals will post -1.38 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of TTPH. Flagship Harbor Advisors LLC acquired a new position in Tetraphase Pharmaceuticals during the 2nd quarter worth about $104,000. Cubist Systematic Strategies LLC lifted its holdings in Tetraphase Pharmaceuticals by 232.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 35,537 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 24,837 shares during the period. Canada Pension Plan Investment Board acquired a new position in Tetraphase Pharmaceuticals during the 2nd quarter worth about $179,000. Dynamic Technology Lab Private Ltd lifted its holdings in Tetraphase Pharmaceuticals by 322.1% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,108 shares of the biopharmaceutical company’s stock worth $234,000 after buying an additional 58,079 shares during the period. Finally, Royce & Associates LP acquired a new position in Tetraphase Pharmaceuticals during the 2nd quarter worth about $556,000. Institutional investors and hedge funds own 40.93% of the company’s stock.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

See Also: Market Capitalization in the Stock Market

The Fly

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.